Dr. Reddy’s aims to join India’s top five pharma players by growing 15–16%, driven by new launches, partnerships, and R&D-backed brand expansion.
Dr. Reddy’s Laboratories has mapped a clear ambition for its India business: to rank among the country’s top five pharmaceutical companies. M.V. Ramana, Chief Executive Officer of Branded Markets (India and Emerging Markets), spelled out the plan after the company reported its fourth quarter results.
“We look into getting into the top 5 (in the India market). We have to grow much more than the market and grow 15–16%,” Ramana said, framing the company’s growth target for India. That ambition builds on a strong quarter: net profit in January–March rose 22% year-on-year to ₹1,593.90 crore, while revenue climbed 20% to ₹8,506 crore.
India delivered a 16% increase in revenue for the full year ended March. “What is critical is in terms of the portfolio we are able to offer and how we grow our existing brands,” Ramana told Economic Times. He pointed to a second engine: partnerships with innovators that bring new treatments into India. “These innovations are picking pace,” he added.
The company credited its growth to successful product launches, higher US revenues, and integration of its Nicotine Replacement Therapy unit in Europe. For the full year, net profit rose 2% to ₹5,655 crore and revenue reached ₹32,553.50 crore. “We will continue to strengthen and grow our core businesses through portfolio management and operational excellence, while pursuing strategic partnerships and inorganic growth opportunities,” Co-Chairman & Managing Director G.V. Prasad said in a press release.
Ramana highlighted recent launches that embody the innovation push. “One such opportunity is the product we have launched is toripalimab for nasopharyngeal carcinoma. We see that it is gaining traction and getting good results based on the feedback from doctors.” He noted two more launches this quarter: “a respiratory vaccine for infants. This product has done well globally. Similarly another innovation we are bringing in is a product for allergy—the first product approved by CDSCO in this space.”
The strategy extends beyond prescription drugs. Dr. Reddy’s entered a joint venture with FMCG major Nestlé last year to tap into health and wellbeing products. “That integrated well and is expected to continue to grow,” Ramana said.
On the potential impact of US tariffs, the company remained cautious. With no clear guidance yet, officials declined to estimate any financial effect.
As Dr. Reddy’s pushes to outpace market growth and secure a top-five position, its blend of brand nurturing, strategic alliances, and fresh R&D offerings will determine whether it can turn its aspiration into reality.
